Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novantrone (mitoxantrone HCl) Injection February 2009
Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and Remand for Further Review
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Effect of IFN β-1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.
Dilantin
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
Immune competence after alemtuzumab treatment of multiple sclerosis.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Adaptive myelination from fish to man.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
New data from ENDORSE show positive results continued over five years with TECFIDERA® (dimethyl fumarate) in a wide range of multiple sclerosis patients
Biogen Idec submits application to FDA for approval of PLEGRIDY™ (peginterferon beta-1a) in multiple sclerosis
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.
Treatment of neurological injury with thymosin β4.
Breastfeeding and multiple sclerosis.
ARESTIN®

Pages